Thomas H McLean

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Positive Breast Cancer

Molecular Dynamics Simulations

Tyrosine Kinase

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Heike Schonherr, Pelin Ayaz, Alexander M Taylor, Jessica B Casaletto, B Barry Toure, Demetri T Moustakas, Brandi M Hudson, Roberto Valverde, Songping Zhao, Patrick J O'Hearn, Lindsey Foster, Dina A Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M Mader, Alessandro A Boezio, Thomas H McLean, Rongfeng Chen, Yanxia Wang, David E Shaw, James Watters, Donald A Bergstrom
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Heike Schonherr, Pelin Ayaz, Alexander M Taylor, Jessica B Casaletto, B Barry Toure, Demetri T Moustakas, Brandi M Hudson, Roberto Valverde, Songping Zhao, Patrick J O'Hearn, Lindsey Foster, Dina A Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M Mader, Alessandro A Boezio, Thomas H McLean, Rongfeng Chen, Yanxia Wang, David E Shaw, James Watters, Donald A Bergstrom
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Heike Schonherr, Pelin Ayaz, Alexander M Taylor, Jessica B Casaletto, B Barry Toure, Demetri T Moustakas, Brandi M Hudson, Roberto Valverde, Songping Zhao, Patrick J O'Hearn, Lindsey Foster, Dina A Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M Mader, Alessandro A Boezio, Thomas H McLean, Rongfeng Chen, Yanxia Wang, David E Shaw, James Watters, Donald A Bergstrom
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Heike Schonherr, Pelin Ayaz, Alexander M Taylor, Jessica B Casaletto, B Barry Toure, Demetri T Moustakas, Brandi M Hudson, Roberto Valverde, Songping Zhao, Patrick J O'Hearn, Lindsey Foster, Dina A Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M Mader, Alessandro A Boezio, Thomas H McLean, Rongfeng Chen, Yanxia Wang, David E Shaw, James Watters, Donald A Bergstrom
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Alessandro A Boezio, Lucian DiPietro, Adam Frost, Fabrizio Giordanetto, Erika Paige Hamilton, Katherine Harris, Michael J Holliday, Tamieka L Hunter, Amanda Iskandar, Yongli Ji, Alexandre Larivée, Jonathan R LaRochelle, Andre Lescarbeau, Fabien Llambi, Brenda Lormil, Mary M Mader, Brenton G Mar, Iain Martin, Thomas H McLean, Klaus Michelsen, Yakov Pechersky, Erika G Puente, Ramin Samadani, Alison M Schram, Kelley Shortsleeves, Sweta Swaminathan, Shahein Tajmir, Gege Tan, Yong Tang, Roberto Valverde, Bryan Wehrenberg, Jeremy Wilbur, Bret R Williams, Hongtao Zeng, W Patrick Walters, Beni B Wolf, David E Shaw, Donald A Bergstrom, James Watters, Brian K Shoichet, Pascal D Fortin, D Randal Kipp
Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer discovery (2023)